Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Combination Chemotherapy and Monoclonal Antibody Therapy Followed by Vaccine Therapy in Treating Patients With Mantle Cell Lymphoma
This study has been completed.
Study NCT00020215 Information provided by National Cancer Institute (NCI)
First Received: March 2, 2007 No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Stage IV Mantle Cell Lymphoma
Stage I Mantle Cell Lymphoma
Stage III Mantle Cell Lymphoma
Additional conditions recognized in this trial
Lymphoma
Lymphoma, Mantle-Cell
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
autologous tumor cell vaccine
cyclophosphamide
doxorubicin
etoposide
filgrastim
keyhole limpet hemocyanin
prednisone
rituximab
sargramostim
vincristine
Additional drug interventions recognized in this trial
Etoposide phosphate
Keyhole-limpet hemocyanin
More general drug interventions related to this trial
Adjuvants, Immunologic
Alkylating Agents
Anti-Inflammatory Agents
Antibiotics, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Antineoplastic Agents, Phytogenic
Antirheumatic Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
